BRAF V600E inhibition in anaplastic thyroid cancer

New England Journal of Medicine

Volumn 368, Issue 7, 2013, Pages 684-685

  Rosove, Michael H ^a   Peddi, Parvin F ^a   Glaspy, John A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; PACLITAXEL; VEMURAFENIB;

ADULT; ANAPLASTIC THYROID CANCER; AREA UNDER THE CURVE; BRAF GENE; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; DYSPHAGIA; DYSPNEA; ENZYME INHIBITION; GENE MUTATION; HOARSENESS; HUMAN; INTENSIVE CARE UNIT; LARYNGOSCOPY; LETTER; LYMPHADENOPATHY; MALE; MUTATIONAL ANALYSIS; NECK TUMOR; OXYGEN THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PULSE OXIMETRY; REAL TIME POLYMERASE CHAIN REACTION; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TRACHEOSTOMY; VOCAL CORD PARALYSIS;

EID: 84873641344     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1215697     Document Type: Letter

References (5)

1. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404.
2. Takano T, Ito Y, Hirokawa M, Yoshida H, Miyauchi A. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer 2007;96:1549-53.
3. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
4. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012;366:2038-40.
5. Nehs MA, Nucera C, Nagarkatti SS, et al. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology 2012;153:985-94.